Contrafect Corp (CFRX)

[trickledownfacists]

$CFRX they added 2 more trial sites Jan 8th. 39 now.

[trickledownfacists]

$CFRX
Data at 60% enrollment.
Enrolling since 2019
37 trial sites
14 day follow up

A N Y D A Y N O W

[trickledownfacists]

Added

[that_little_voice]

Nader who is a convicted individual, being sued by three people for breach of fiduciary responsibility and insider enrichment author of religious books and worked at a Jewelry store before being a CEO that dumped the majority of his shares last year into the pump?

What a solid candidate.

Again, look at the backgrounds of the board and management team. Look at the percent ownership of institutional investors. Look at the banks that raised them money. Look at the conferences they present at. Look at the non-dilutive grant money they received. Look at how they focus on the trials and science and not update calls every month like they are running a time share program.

There is little doubt in my head that you are part of their PR campaign and are compensated to post.

[trickledownfacists]

Bullish

[Chuckles759]

We have an immigrant that went from anti-American to mainstream businessman leading a multi-billion dollar company that is about to bring amazing medical breakthroughs to the entire world....

....sorry...what company were you comparing CytoDyn to again ???

[that_little_voice]

They don't have 20 PR/IR firms on the payroll. Some people actually believe in letting the science speak rather than BS. Look at our team and board. Who do you got?

[Chuckles759]

Amazing.

And I'm suspecting all that capital infusion created such a ghost town here?

[that_little_voice]

HAHAH you shook following me around. Too bad they already got CARB-X money twice. Too bad they got $50m from big name funds and too bad Pfizer invested in us 2X. Your CYDY dog shit only gets toxic money. CFRX insiders don't sell, your insiders dump as much as they can.

[Chuckles759]

Helllllloooo.....I heard that_little_voice's also have something little... and that includes bank accounts...

BARDA's would touch this with your mother-in-law.....

[that_little_voice]

Crazy this board is so quiet. Lets wake it up. BARDA decision any week and top line data late Q1 early Q2 2021.

Sleeping giant

[$5.95akadawson-m]

Hey Trickledownfacists: Can you do a favor for me? This is only good news Friday info: but can you make it a point not to get banned again? I really value your input on this board and SEEL and, being so selfish, I look forward to your enthusiasm and posts.

I don't know how you got banned before, but please, just put that person on ignore, so you can't write a post

Okay?


See, all good news...

[Franklin5]

That's BS. Thanks for the find here.

[trickledownfacists]

Went big into SEEL. Still think his is a winner but a few months out before any trial news

[trickledownfacists]

I've been banned.

[Franklin5]

Fintels not great so don't buy it's info.When you coming back to stocktwits

[trickledownfacists]

Just saw it on fintel

[Franklin5]

Any proof besides Fintel?

[trickledownfacists]

Looks like federated sold all their shares.

[sushifishman]

Poor Poor TickleDown is Ticked

He missed the boat on CVM

Said it would be below $10 this week and he would add at $9.22

He seems Angry

Cheers

Read all about it here

https://seekingalpha.com/instablog/50299941-north-shore-research/5437459-cel-sci-idmcs-last-word-continue

[Franklin5]

No one cares. Cheers.

[sushifishman]

Out at $6.23

My work is done here!

Cheers!

[sushifishman]

Hello CFRX Team

Trickledown has been suspended here for violating their terms of service.

He was also suspended on StockTwits for violating their terms of service

His anger at me is unfounded. He is the one that broke the terms of service, not me.

Good luck, I will be exiting my short position by end of day.

I dont want to be caught on a short squeeze as I rarely ever short a stock



Cheers!

[sushifishman]

Short This Pig

The PUMP is over

I shorted at $6.75

Will close out my position at $5.50

Stop loss at $7.25

[sushifishman]

Address?

What you talking bout Willis?

You seem angry

Cheers!

[trickledownfacists]

Waiting on that address.....

[trickledownfacists]

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., F.A.C.P., President, Chief Executive Officer, and Chairman of ContraFect, will deliver the keynote address to open Maxim’s Infectious Disease Virtual Conference to be held on May 5, 2020. Dr. Pomerantz will discuss the urgent need for new antimicrobials and the medical attributes required to provide the basis for a renaissance in the anti-infectives sector. Dr. Pomerantz will also virtually present the Company’s portfolio and platform technology of DLAs during a panel discussion of “Non-antibiotic Anti-infectives.”
Keynote Presentation Details:

Keynote Presentation Title: The Rise of Antimicrobials
Time and Date: Tuesday, May 5, 2020, 10:00 a.m. ET

Panel Discussion Details:

Panel Session Title: Non-antibiotic Anti-infectives
Time and Date: Tuesday, May 5, 2020, 10:30 a.m. ET

[trickledownfacists]

Remember
Breakthrough designation approved.
The market HAS NOT valued that in yet.
Fast tracked.
Still enrolling.
Still adding sites.
Ceo says
$700M
-$1.5B in sales a year.
Easy
$5B
valuation.

If they enroll 10 patients a month at each site they will have 60% enrolled in 3.5 months. Been enrolling for 3 months now.
DATA READ OUT AFTER 60% ENROLLMENT!!!

Pfizer owns almost 10% and their VP is in the board of CFRX.

12.5M float with 10.5M shares held by insiders and funds.

Between PFE and Federated they own 30% of all shares!! Pfizer has the option to buy 10% more at a price over $12

[trickledownfacists]

Could be a HUGE week coming up. Could test $10 or higher

[trickledownfacists]

Fake walls out up everywhere

[trickledownfacists]

ANOTER TRIAL SITE ADDED

[trickledownfacists]

ANOHER TRIAL SOTW ADDED.

[trickledownfacists]

Great consolidation.

[trickledownfacists]

Crushing as usual.

$17 pt

[trickledownfacists]

Zacks: we have a PT of $30
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/CFRX-Interim-Futility-Analysis-for-Phase-3-DISRUPT-Trial-Once-60-Enrolled-article/default.aspx

[trickledownfacists]

215% upside...
https://www.directorstalkinterviews.com/contrafect-corporation-consenus-indicates-potential-215-1-upside/412811942?amp

[$5.95akadawson-m]

Thank you!

[trickledownfacists]

Beaten down. Huge news two weeks ago but lost in the covid panic.

Beaten down from $15

[$5.95akadawson-m]

Any news or just beaten down?

[trickledownfacists]

Crushing!

[trickledownfacists]

Continuation next week.

Breakthrough designation approved.
The market HAS NOT valued that in yet.
Fast tracked.
Still enrolling.
Still adding sites.
Ceo says $700M-$1.5B in sales a year.
Easy $5B valuation.

If they enroll 10 patients a month at each site they will have 60% enrolled in 3.5 months. Been enrolling for 3 months now.
DATA READ OUT AFTER 60% ENROLLMENT!!!

Pfizer owns 10% and their VP is in the board of CFRX.

12.5M float with 10.5M shares held by insiders and funds.

Between $PFE and Federated they own 30% of all shares!! Pfizer has the option to buy 10% more at a price over $12.

[trickledownfacists]

That halt was the most ridiculous I've ever seen

[trickledownfacists]

Halted

[Dajuca123]

Huge upside

[trickledownfacists]

Crushing

[trickledownfacists]

Cheapest bio ever

[trickledownfacists]

So cheap,

Break through designation still not valued in.

[trickledownfacists]

The average market cap for large companies with BTD drugs is $138B

The average market cap for small cap companies who receive BTD is $8.3B

Cfrx market cap is $165M

[trickledownfacists]

FDA grants ‘break­through’ sta­tus to an­tibi­ot­ic al­ter­na­tive as Con­tra­Fect rush­es to join fight against su­per­bug

Amber Tong

Methicillin-resistant Staph aureus (Shutterstock)

An ex­per­i­men­tal drug that promis­es to be the first an­ti-in­fec­tive agent to prove su­pe­ri­or to van­comycin — an an­tibi­ot­ic ap­proved in 1958 — has notched the FDA’s “break­through” sta­tus.

Roger Pomer­antz
Con­tra­Fect said the des­ig­na­tion was based on Phase II da­ta in which exe­ba­case was test­ed against a su­per­bug known as me­thi­cillin-re­sis­tant Staph au­reus, or MR­SA. In a sub­group analy­sis, the clin­i­cal re­spon­der rate at day 14 was 42.8% high­er than that among those treat­ed with stan­dard of care, the com­pa­ny said (p=0.010).

The 21% re­duc­tion in 30-day all-cause mor­tal­i­ty, how­ev­er, was not sta­tis­ti­cal­ly sig­nif­i­cant with p=0.056.

Demon­strat­ing su­pe­ri­or­i­ty marks a first for the MR­SA field, em­pha­sized Roger Pomer­antz, who jumped from Seres to be­come CEO for Con­tra­Fect last April. Al­ler­gan’s Dal­vance, a struc­tur­al rel­a­tive to van­comycin, was ap­proved based on non-in­fe­ri­or­i­ty.

Con­tra­Fect is now con­duct­ing a piv­otal Phase III study to ex­am­ine exe­ba­case’s ef­fi­ca­cy in all in­fec­tions caused by Staph au­reus, in­clud­ing right-sided en­do­cardi­tis.

Cara Cassi­no
“Based on our in­ter­ac­tions with the FDA re­gard­ing stream­lined de­vel­op­ment of exe­ba­case, this sin­gle Phase 3 study, in ad­di­tion to the full pack­age of da­ta gen­er­at­ed to date, may serve as the ba­sis of a Bi­o­log­ics Li­cense Ap­pli­ca­tion for FDA re­view and po­ten­tial ap­proval of exe­ba­case,” CMO Cara Cassi­no said in a state­ment.

MR­SA, which com­pris­es a group of Gram-pos­i­tive bac­te­ria, can cause in­fec­tions in the skin, the heart, the res­pi­ra­to­ry sys­tem, bone and joint, and even the cen­tral ner­vous sys­tem.

Michael Messinger
Tak­ing a page from bac­te­rio­phages — virus­es that in­fect bac­te­ria — Con­tra­Fect’s drug is a cell wall hy­dro­lase en­zyme, or lysin, that in­duces bac­te­r­i­al death by punc­tur­ing the cell wall. Its in­ven­tor, Vin­cent Fis­chet­ti of Rock­e­feller Uni­ver­si­ty, calls it an an­tibi­ot­ic al­ter­na­tive.

The com­pa­ny fore­casts a $700 mil­lion mar­ket for the MR­SA bac­teremia in­di­ca­tion pro­vid­ed that exe­ba­case de­liv­ers in Phase III and gets the su­pe­ri­or­i­ty la­bel, CFO Michael Messinger told End­points News. They are al­so gun­ning for an ex­pand­ed la­bel cov­er­ing all Staph au­reus.

Author

[$5.95akadawson-m]

FDA approves Execabase this morning!

Stock up.

Whole market taking a beating because of Covid-19.



ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis